trending Market Intelligence /marketintelligence/en/news-insights/trending/MODGWB3p88hEhE3_b1onug2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neoleukin Therapeutics seeks to raise $75M via common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Neoleukin Therapeutics seeks to raise $75M via common stock offering

Neoleukin Therapeutics Inc. seeks to raise about $75 million in gross proceeds from a public offering of its common stock.

The Seattle-based biotechnology company is offering 8,925,000 shares for $8.40 each. Underwriters have also been given an option to buy up to an additional 1,338,750 common shares, Neoleukin Therapeutics said in a Dec. 17 press release.

The offering is expected to close Dec. 20, the company added.

Net proceeds will primarily be used to advance the clinical development of the company's experimental treatment NL-201. The company will also use the proceeds to develop its preclinical pipeline and to fund working capital and for general corporate purposes, including capital improvements to properties it leases.

BofA Securities, Piper Jaffray and Guggenheim Securities are the joint book-running managers, and Canaccord Genuity is the lead manager for the offering.